Kraig Biocraft Laboratories Receives $1.5 Million in Capital Funding

Company is in its strongest financial position ever, having raised $8 million in 16 months

ANN ARBOR, Mich., – April 14, 2022– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that it has received another $1.5 million from YAII PN, Ltd (“YAII”) a fund managed by Yorkville Advisors Global, LP (“Yorkville”). The $1.5 million received this week is the second half of a $3 million fund agreement signed with YAII in January 2022. This $3 million and those from the previously announced transactions account for an $8 million total YAII investment into Kraig Labs over the past 16 months.

The Company is well underway, putting this impact capital to work, strengthening its production operations. Over the last nine months, the Company has deployed capital to build additional production capacity and bring key onsite quality control systems online. These renovations included building out custom-designed rearing rooms, purchasing and installing custom automated production equipment, and planting onsite mulberry to support year-round operations. This work also included the construction of a fully operational molecular biology laboratory that provides onsite and in-process quality control, mirroring the capabilities of the Company’s U.S.-based R&D labs.

“This capital is allowing us to make strategic investments in critical processing, facilities, and equipment that have dramatically enhanced our production capabilities and capacity. Prodigy Textiles is now fully operational and beginning to fulfilling its mission of bringing eco-responsible and cost-effective spider silk to the global textile markets,” said Company COO, Jon Rice.

Maxim Group LLC acted as the sole placement agent for this capital raise.

The Company thanks Maxim Group LLC and Yorkville for their continued trust and confidence in Kraig Labs and its disruptive innovation of the technical textile markets.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories Collaboration Between US and Vietnam Teams Completes First 100% Genetic Screening for In-Process Spider Silk Production

ANN ARBOR, Mich., – March 7, 2022– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announced significant advancements in its Vietnam based production facility, Prodigy Textiles.

The collaboration between the Company’s US and Vietnam lab teams has resulted in their first complete genetic screening of in-process production silkworms. This fifth generation of silkworms, now being reared in Vietnam, is the first production cycle of silkworms at the factory to receive 100% genetic screening. This level of testing, for Kraig Labs, was previously only available at the Company’s R&D headquarters is now being fully transferred to the Vietnamese lab team. 

Earlier this month, the Company flew in an expert trainer to provide hands-on training with new staff members of its expanded R&D team at Prodigy Textiles. In the coming weeks, Kraig Labs’ senior scientist will be at Prodigy Textiles to build on that training and bring additional competencies to the lab in Vietnam. Working together, the Prodigy and Kraig Labs’ teams will screen the sixth generation eggs, the largest expected single production cycle in the Company’s history, and prepare the lab for its expanding role in supporting silk production.

“Transferring this screening technology to Prodigy was the final element needed for our operations team in Vietnam to complete scaling up output to match our facility capacity,” said COO Jon Rice. “With our lab team at Prodigy taking over this crucial testing, I believe our team in Vietnam is now ready to boost monthly silk production targets by 20-50 times current levels.”

In the coming months, the Company also expects to begin harvesting is own supply of fresh mulberry that it began planting in December of last year. This onsite supply will play a critical role is allowing the Company to continue to expand the production of spider silk analog fibers and yarns and to deliver materials to its current and anticipated future end market channel partners.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

USPTO Publishes Two Key Kraig Biocraft Laboratories Patent Applications

ANN ARBOR, Mich., – February 16, 2022– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that the United State Patent and Trademark Office (USPTO) has recently published two key patent applications filed by the Company. These two USPTO patent applications build on Kraig Labs’ innovative recombinant spider silk technologies.

These USPTO patent applications are based upon three provisional patents filed in July of 2020. The two consolidated applications were filed in July of 2021. This is the first opportunity for the public to take a look under the hood to see what this powerful intellectual property encompasses and the opportunities they may unlock.

The first of these USPTO applications, titled “Synthesis of High Molecular Weight Proteins Using Inteins”, reinvents the Company’s approach to manufacturing large-format spider silk protein. This new technology allows for the automated self-assembly of target proteins within the silkworm. This process allows for the opportunity to reach beyond the limits of current protein synthesis technologies. 

This new approach, using the auto-processing capabilities of Inteins, creates the opportunity to create plug-and-play blends of numerous spider silk proteins that are not inhibited by the current size limitation for targeted gene knock-in knock-out transformations. 

The second of these USPTO applications, titled “Synthesis of Non-Native Proteins in Bombyx Mori by Modifying Sericin Expression”, moves beyond the heavy chain fibroin and creates opportunities for co-production of non-fibrous proteins within sericin. Sericin is the stick glue-like protein holding the silk fibers together, making up roughly 20% of the cocoon, and is broadly considered a waste product. 

This invention seeks to leverage this untapped resource to increase the production of target proteins. These target materials include a range of possible applications, including therapeutic and pharmacological proteins. The current production systems for these proteins are inefficient and, therefore, very expensive. This new process opens the possibility for large-scale production materials such as elastin, keratin, human collagen, and many more at comparatively very low costs.

“Our research team continues to deliver, developing novel and innovative applications for our gene-editing technologies,” said COO Jon Rice. “While our production operations in Vietnam remain laser-focused on the large-scale commercial production of spider silk textiles, our lab is busy executing on the technology roadmap to secure Kraig Labs’ future and legacy.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories Delivers Dragon Silk to Spydasilk Enterprises

ANN ARBOR, Mich., – February 10, 2022– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces the delivery of Dragon Silk yarn to Spydasilk Enterprises (“Spydasilk”). Spydasilk is a Singapore-based joint venture between Kings Golden Harvest (“Kings”) and Kraig Labs focused on the commercial sale of luxury streetwear and apparel derived from spider silk.

Spydasilk will process the Company’s recombinant spider silk yarn, trade named Dragon Silk, into premium fabrics and garments. Spydasilk expects to make these products available through a combination of direct sales and traditional retail channels.

“Our partnership with Kings and the Spydasilk brand gives us a very exciting direct-to-consumer sales channel,” said Jon Rice, COO of Kraig Labs. “This first small shipment of Dragon Silk will be used to develop the first fabrics in the Spydasilk family of products. Our unique and proprietary spider silk technology paired with Kings branding and marketing expertise should elevate the Spydasilk brand and create sales opportunities for the Company.”

“We are thrilled with the arrival of the Dragon Silk samples in Singapore. This will unfold the progressive plan to work with many big brands with this material that is both associated with modern science as well as sustainable. The counterparties involved are excited to push out the concepts that were in the pipeline since the beginning of the discussions,” said Spydasilk and Kings Group marketing director, Dai Jiajun.

In the coming weeks, the Company expects to be ready to formally launch the Spydasilk website and brand.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories Closes Additional Funding Agreement

ANN ARBOR, Mich., Jan. 20, 2022 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces the completion of an additional $3 million funding agreement with Yorkville Advisors (“Yorkville”). These additional funds, together with those from the previously announced transactions, account for an $8 million total Yorkville investment into Kraig Labs.

As a result of this successful capitalization program, the Company has elected not to renew the previously anticipated reverse stock split. The Company is focused on advancing the commercialization of spider silk. Kraig Labs will increase its capital deployment into key priorities, including commercialization, advanced research and development, and expansion at the Prodigy Textiles factory.

“This funding allows us to advance our strategic plans and transform our resources into more robust operations. We will immediately invest these capital expenditures to accelerate commercialization at Prodigy Textiles production facilities,” stated Company COO, Jon Rice.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories Prepares to Ship Finished Dragon Silk Yarn From Vietnam Factory

ANN ARBOR, Mich., Jan. 18, 2022 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces it has completed production of the first Dragon Silk yarn produced entirely in Vietnam. The finished recombinant spider silk yarn was spun from raw spider silk produced at Prodigy Textiles, the Company’s subsidiary located in Quang Nam province, Vietnam.

Today’s announcement marks a significant milestone for Kraig Labs, Prodigy Textiles, and the large-scale production of recombinant spider silk. This production run of Dragon Silk exhibits Prodigy Textiles’ full integration into Vietnam’s substantial silk textile industry. Vietnam produced nearly 1,000 metric tons of mundane silk in 2020.1   This same supply chain was used, from start to finish, to create the first Dragon Silk made entirely in Vietnam.

While Prodigy Textiles remains focused on ramping up the output of recombinant spider silk cocoons, these supporting vendors will play an essential role in processing that silk into finished goods for a wide range of consumer markets.

The Company plans to ship this Dragon Silk yarn to SpydaSilk Enterprises, in Singapore, a joint venture partially owned by the Company, for weaving into fabrics and finished garments.  

Over the coming months, Prodigy will continue to leverage this expanded silk production success to address the material needs of SpydaSilk and make additional materials available for purchase to fill the numerous and backlogged material requests it has received.

“The successful completing of this Dragon Silk yarn produced entirely utilizing the Vietnamese supply chain is a substantial achievement for the Kraig Labs and our vision for eco-responsible and cost-effective spider silk,” said COO Jon Rice. “I am extremely proud of the team at Prodigy for achieving this major milestone, while overcoming several obstacles to get this done as quickly as they did. 2022 is positioned to be a breakout year for the commercial sales of Dragon Silk and our broader recombinant spider silk technologies.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories Receives Equipment for Onsite Testing and Screening of Transgenic Technology at Prodigy Textiles

ANN ARBOR, Mich., Jan. 04, 2022 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces it has taken delivery of key lab equipment to Prodigy Textiles, the Company’s Vietnam based subsidiary, to support onsite testing and screening of spider silk transgenic technologies.

Over the next few weeks, the Company’s US-based research team will work closely with the Prodigy team to complete equipment installation and conduct training. Once online, this equipment will allow for the complete transfer of all genetic screening and selection testing, for production operations, to Prodigy’s onsite lab.

The significance of this advancement in the Company’s production operation cannot be overstated. Previously all genetic testing was limited to Kraig Labs US R&D headquarters. COVID-related transportation and shipping restrictions over the last 24 months have meant that critical testing was delayed and, in some cases, not possible. This, in turn, forced the Company to lower its output at Prodigy to ensure production quality. With onsite process screening, Prodigy will be able to safely and effectively scale up operations and take full advantage of Prodigy’s new facilities. The goal is to run at maximum facility capacity consistently.

Implementing in-process quality testing is yet another example of the Company’s efforts to build a completely autonomous production operation at Prodigy Textiles. The Company believes that, in blending the most advanced technologies available with the rich history of silk production in Vietnam, it is building an advanced scalable system for large-scale recombinant spider silk production.

“Once online, this equipment will allow our production team to floor the gas pedal on production,” said COO Jon Rice. “Travel and shipping delays in 2020 and 2021 demonstrated that Prodigy needed to have the tools in place to stand on its own. This onsite lab is the final element of that equation. In-process testing will give our team the tools and confidence needed to run our facilities at maximum capacity in very short order.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

This entry was posted on by .

A Holiday Letter from Kraig Biocraft Laboratories’ CEO

ANN ARBOR, Mich., Dec. 21, 2021 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), the leading developer of spider silk-based fibers, announces today that Kim Thompson, the Company’s CEO, issued a letter to shareholders. The full text is as follows:

With the holiday season upon us, I’d like to reach out to all of our team members, especially our shareholders, to express my appreciation and great expectations for our production and commercialization in 2022.

Yes, the holidays are just around the corner and we’re heading into 2022 in what is, by far, our strongest financial and fundamental position, so we’re excited about the coming advancements for Kraig Labs and anticipate spider silk’s commercial success in the New Year.

As you know, 2021 presented many new challenges, mostly centered on navigating the COVID-19 regulations, but addressing these with smart solutions has enriched Kraig and Prodigy Textiles, our Vietnamese subsidiary.

For example, after confirming proof of our production concept, we introduced the first automation into Prodigy’s workflow five months ago. This equipment has drastically improved our material handling and has allowed us to grow the size of our silkworm colony without bringing in additional labor. More importantly, this equipment is playing a key role in our quality control system and is the backbone on which we are building out our production capacity. This upgrade to our operations has delivered a sustained quality to our silkworm colony that was previously not attainable.

However, the next phase of this initiative is a game-changer; Prodigy’s fully equipped laboratory is a new onsite capacity that was designed to mirror the capabilities of Kraig’s US R&D headquarters and provide in-process quality and genetic screening. Partnered with the automated production equipment, the new lab will provide Prodigy with the same world-class genetic screening capabilities that were critical in Kraig’s creation of spider silk transgenics. Once these capabilities are online, we anticipate judiciously scaling output to metric tons.

I believe that the importance of that milestone cannot be overstated, because it positions us to move on to the next chapter of our business model. Fulfilling the years’ long material request backlog, which is key to securing additional commercialization agreements. Plus, we plan on working with some inventors and product developers whose imagination may take spider silk to yet unknown frontiers.

Dr. Miller, who completed his Ph.D. and postdoctoral work at Yale, joined Kraig’s R&D team in July. He’s already made significant contributions in advancing the commercialization of the Company’s new lines of nearly pure spider silk and the silkworm immunity enhancement program. Dr. Miller has recharged our R&D team with new energy and expertise. His contributions and ideas have opened the potential for several additional revenue streams reaching far beyond textiles. We’re excited to see what he unveils over the next year.

Of course, most of these breakthroughs were made possible by the $5 million funding that the Company secured through its partnering with a substantial investment bank based in New York. This marks the largest capital investment in the Company’s history. Drawing this type of attention and confidence from sophisticated investors is exciting and reaffirming of our belief in the markets for spider silk and the future of Kraig Labs. As our production operations continue to grow, we are positioned to see additional potential institutional funding in 2022.

Kraig Labs and Prodigy Textiles kindly thank you for your trust and continuing support, because we accomplished so much, together. We hope that you are surrounded by loved ones this holiday season and that, like Kraig, your best days remain ahead.

With warmest holiday greetings and best wishes for the New Year,

Kim Thompson and the entire Kraig Labs’ family

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories Spider Silk Featured on BBC Earth Series

ANN ARBOR, Mich., Dec. 10, 2021 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), the leading developer of spider silk-based fibers, announces today that its spider silk was featured in a new episode of the BBC Earth’s “Inspired By Nature” series.  

To view a portion of the episode, please go to BBC Earth’s Facebook page and look for the “Bulletproof material made from a spider’s web” post at: https://www.facebook.com/bbcearth/videos/427557478860613/

“We don’t need to reinvent the wheel, we don’t need to try to do something better than nature has, we simply need to find ways to reproduce what nature has already done,” said Jon Rice to BBC Earth when asked where Kraig Labs draws its inspiration.

Sample images of the Company’s recombinant spider silk silkworms and materials featured in the episode found on the Company’s website at www.kraiglabs.com/InspiredByNature

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About BBC Earth

Celebrating nature, science, space and the human race, BBC Earth brings you face to face with heart-pounding action, mind-blowing ideas and the sheer wonder of being part of this amazing planet we call home.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories Expands Production Footprint, Building Self Reliant Supply Chain

ANN ARBOR, Mich., Dec. 09, 2021 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), the leading developer of spider silk-based fibers, announces today that it is expanding the footprint of its Vietnam based operations with the planting of several acres of mulberry trees at its recombinant spider silk production campus.

Agricultural production cycles in Vietnam have historically left the Company with limited access and high costs for the continuous supply of fresh mulberry needed during the winter months. With the expansive lands available in its new operations headquarters, the Company has begun planting mulberry on the more than 7 acres of fertile field land it controls.

The Company will continue to partner with local farming cooperatives to source the majority of its mulberry during the summer months. However, these onsite fields will eliminate the need for seasonal slowdowns that have impacted winter production.   Previously, the Company was forced to purchase mulberry from the broader markets. Direct control over its own mulberry fields will remove concerns of pesticide overspray from adjoining farms that have been difficult to monitor in previous winters.

“Kraig Labs has always prided itself on being scrappy and self-reliant. Our team at Prodigy Textiles is no different. The move to this new larger facility and these mulberry fields allow us the ability to create a truly self-sustaining spider silk production campus,” said COO Jon Rice. “The final piece of this equation will be the lab equipment scheduled for installation later this month. With that, Prodigy Textile will have the means, ability, and facilities to stand on its own as the world’s first truly sustainable supplier of spider silk super fibers.”

Sample images of the new production campus and the mulberry fields can be found on the Company’s website at www.kraiglabs.com/MulberryFields.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

This entry was posted on by .